This study is testing new drug combinations for advanced kidney cancer. It's a Phase II trial, meaning researchers are checking if the new treatments work and are safe. The study is for adults who haven't had other treatments for their kidney cancer, which has spread to other parts of the body. Participants will be split into two groups. One group will get the new drugs, botensilimab and balstilimab, while the other will get existing drugs, ipilimumab and nivolumab. Treatment could last up to 96 weeks. To join, patients need to meet certain health criteria and provide a tumor sample.
- Study involves multiple visits over a maximum of 96 weeks.
- Participants will be randomly assigned to one of two treatment groups.
- Potential side effects from treatment could occur.
How understandable was the trial content above?
Hard to understand
Easy to understand